Gemin X Pharmaceuticals (Malvern, PA) focused on developing novel treatments for cancer, closed a $38M Series C financing. Participants include Caxton Advantage Life Sciences Fund, Caxton Global, Sanderling Ventures, H.I.G. Ventures, CDP/Vantage Point, ProQuest, Merlin BioMed Group, HBM Partners, Canadian Medical Discoveries Fund, Ontario Teachers’ Pension Plan Board, SoftBank Life Science, Business Development Bank of Canada, Solidarity Fund QFL, and Pinnacle Bioventures.